What American Well (AMWL) Said on Its Q3 Earnings Call

Amwell (AMWL) reported Q3 earnings with virtual primary care visits up 41% YoY, but total platform visits down 30.5%. Gross profit was $26M with a 53% margin. Q4 revenue is forecasted at $48M-$50M, with adjusted EBITDA expected to break even or turn positive. The company raised its full-year 2026 outlook, now expecting revenue of $204M-$206M and a reduced adjusted EBITDA loss. Amwell also discussed potential government contracts, including a nonbinding letter of intent from the VA.

Original reporting
Published Nov 4, 2026, 3:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 3:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What American Well (AMWL) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$AMWLBullishMed
01

Why it matters

The raised guidance and positive outlook could attract short‑term buying, but execution risk around government contracts remains.

02

Market read

Amwell’s guidance upgrade is the primary market‑moving element; peers may benefit indirectly.

03

What to watch

Potential delays in the VA agreement and macro‑economic headwinds could temper revenue growth.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Amwell reported Q3 results with modest profit, improved margins, and a cash pile of $181 M, while noting a decline in total platform visits.

Company-level read

Ticker impact

$AMWLBullishHigh confidence
Context

Amwell raised its full‑year 2026 revenue guidance to $204‑$206 M and narrowed its adjusted‑EBITDA loss to $6.9‑$7.9 M, plus gave a Q4 revenue outlook of $48‑$50 M.

Expected impact

likely upward pressure as investors price in higher revenue and tighter loss guidance

Evidence & confidence

The company disclosed materially better guidance than previously expected, a fresh primary fact that can move the stock.

Market effects

Digital‑health peers may see renewed interest as Amwell’s guidance beat expectations.

U.S. telehealth segment could experience modest buying pressure.

Limited; impact confined to U.S. listed telehealth stocks.

Counterpoint

If the VA contract remains non‑binding, the guidance lift may be overstated, risking a pull‑back.

Key entities

  • American Well (Amwell)

    U.S. digital‑health platform provider (NYSE: AMWL).

  • Department of Veterans Affairs

    Potential source of future revenue pending a binding contract.

Related articles

$AMWLMed

American Well Corp (AMWL) Q3 2026 Earnings Call Highlights: Revenue Beat, Raised Guidance

American Well Corp (AMWL) reported Q3 2026 revenue of $49M, down 12.9% YoY. Subscription revenue fell 22.5% due to churn. Platform visits dropped 30.5% YoY. The VA letter of intent is non-binding, and the DHA contract conversion is pending. CEO Dr. Ido Schoenberg expressed optimism about negotiations and potential growth opportunities. The company expects Q4 adjusted EBITDA breakeven and raised guidance.

$AMWLHigh

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026 BOSTON, November 3 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the third quarter ended September 30,

$AMWLMedAI 8/10

American Well (AMWL) Q2 2026 Earnings Call Transcript

American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.

$AMWLMed

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026 BOSTON, August 4 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30, 2026